Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review

Introduction: Antimicrobial resistance is a major healthcare issue responsible for a large number of deaths. Many reviews identified that PKPD data are in favor of the use of continuous infusion, and we wanted to review clinical data results in order to optimize our clinical practice. Methodology: We reviewed Medline for existing literature comparing continuous or extended infusion to intermittent infusion of betalactams. Results: In clinical studies, continuous infusion is as good as intermittent infusion. In the subset group of critically ill patients or those with an infection due to an organism with high MIC, a continuous infusion was associated with better clinical response. Conclusions: Clinical data appear to confirm those of PK/PD to use a continuous infusion in severely ill patients or those infected by an organism with an elevated MIC, as it is associated with higher survival rates. In other cases, it may allow for a decrease in antibiotic daily dosage, thereby contributing to a decrease in overall costs.

• Publication year

  2023

• Venue

  Antibiotics

• Publication date

  2023-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/antibiotics12061052PMID 37370371PMCID 10295077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study

  2022cited by this paper
• Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections

  2021cited by this paper
• The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group

  2021cited by this paper
• Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections

  2021cited by this paper
• Influence of Concentration and Temperature on Stability of Imipenem Focused on Solutions for Extended Infusion

  2021cited by this paper
• Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach

  2021cited by this paper
• The MOBILISE study: utilisation of ambulatory pumps in the inpatient setting to administer continuous antibiotic infusions—a randomised controlled trial

  2021cited by this paper
• Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance.

  2020cited by this paper
• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

  2020cited by this paper
• Home intravenous antibiotherapy and the proper use of elastomeric pumps: Systematic review of the literature and proposals for improved use.

  2020cited by this paper
• PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA.

  2019cited by this paper
• Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study

  2018cited by this paper
• Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

  2017cited by this paper
• Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study

  2017influential reference
• Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis

  2016cited by this paper
• β-Lactams and β-Lactamase Inhibitors: An Overview.

  2016cited by this paper
• Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa

  2016cited by this paper
• Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.

  2016cited by this paper
• Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

  2016cited by this paper
• A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

  2015influential reference
• CONTINUOUS VERSUS INTERMITTENT INTRAVENOUS MEROPENEM IN SEVERE SEPSIS

  2015cited by this paper
• Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.

  2015influential reference
• Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study

  2014cited by this paper
• Continuous versus intermittent infusion of cefepime in neurosurgical patients with post-operative intracranial infections.

  2014influential reference
• Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa

  2013cited by this paper
• Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.

  2013cited by this paper
• Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

  2012influential reference
• Clinical efficacy of continuous infusion of piperacillin/tazobactam in severe pneumonia patients: a randomized controlled clinical trial.

  2010cited by this paper
• Continuous versus Intermittent Infusion of Oxacillin for Treatment of Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus

  2009cited by this paper
• Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

  2009cited by this paper
• Continuous-Infusion β-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria

  2009cited by this paper
• Pharmacokinetic issues for antibiotics in the critically ill patient

  2009cited by this paper
• Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis

  2009influential reference
• [Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly].

  2009cited by this paper
• Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis

  2009influential reference
• Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial

  2007influential reference
• Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.

  2007cited by this paper
• Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

  2006influential reference
• Pharmacodynamics: relation to antimicrobial resistance.

  2006cited by this paper
• Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection

  2006cited by this paper
• Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.

  2006cited by this paper
• Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis.

  2006influential reference
• Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.

  2006cited by this paper
• Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli

  2006influential reference
• Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.

  2005influential reference
• Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.

  2005influential reference
• The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.

  2005cited by this paper
• Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.

  2003cited by this paper
• Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital

  2002cited by this paper
• Cost‐Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial Pneumonia

  2001cited by this paper
• Evaluating and predicting the ecologic impact of antibiotics.

  2001cited by this paper
• Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.

  2001cited by this paper
• Intermittent and continuous ceftazidime infusion for critically ill trauma patients.

  2000cited by this paper
• Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children

  2000influential reference
• A Pilot Study of the Efficacy of Constant‐Infusion Ceftazidime in the Treatment of Endobronchial Infections in Adults with Cystic Fibrosis

  1999cited by this paper
• Production of beta-lactam antibiotics and its regulation.

  1991cited by this paper
• Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.

  1985cited by this paper
• Aztreonam: the first monobactam.

  1985cited by this paper
• Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929.

  1980cited by this paper
• The structure of cephalesporin C.

  1961cited by this paper
• The structure of cephalosporin C

  1961cited by this paper
• On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ

  1929cited by this paper

• Stability of Nine Time-Dependent Antibiotics for Outpatient Parenteral Antimicrobial Therapy (OPAT) Use

  2025cites this paper
• Modeling of pharmacokinetic/pharmacodynamic parameters in regular intermittent intravenous infusion and translational application of the models in personalized antibiotics dosing

  2025cites this paper
• Continuous infusion of Beta-Lactams in the critically ill: Considerations for global implementation.

  2025cites this paper
• Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections

  2023cites this paper